|
[1]
|
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. Cancer J Clin, 2011, 61(2):69. |
|
[2]
|
He X, Li S, Huang H, et al. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours[J]. Br J Clin Pharmacol, 2011, 71(6):860. |
|
[3]
|
Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels[J]. Nat Rev Cancer, 2005, 5(6):423. |
|
[4]
|
Pettit GR, Temple C Jr, Narayanan VL, et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs[J]. Anticancer Drug Des, 1995, 10(4):299. |
|
[5]
|
Ding XQ, Zhang ZQ, Li S, et al. Combretastatin A-4 phosphate induces programmed cell death in vascular endothelial cells[J]. Oncol Res, 2011, 19(7):303. |
|
[6]
|
Nathan P, Zweifel M, Padhani AR, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer[J]. Clin Cancer Res, 2012, 18(12):3428. |
|
[7]
|
Delmonte A, Sessa C. AVE8062:a new combretastatin derivative vascular disrupting agent[J]. Expert Opin Invest Drugs, 2009, 18(10):1541. |
|
[8]
|
Hori K. Antineoplastic strategy:irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700)[J]. Chemotherapy, 2005, 51(6):357. |
|
[9]
|
Nihei Y, Suga Y, Morinaga Y, et al. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors[J]. Jpn J Cancer Res, 1999, 90(9):1016. |
|
[10]
|
Clémenson C, Jouannot E, Merino-Trigo A, et al. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models[J]. Invest New Drugs, 2013, 31(2):273. |
|
[11]
|
Sessa C, Soria JC, Tolcher A, et al. A phase I pharmacokinetic and pharmacodynamic study of AVE8062, a novel vascular disrupting agent, in patients (PTS) with advanced solid tumors-preliminary results[J]. Ann Oncol, 2009, 20:24. |
|
[12]
|
Morinaga Y, Suga Y, Ehara S, et al. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo[J]. Cancer Sci, 2003, 94(2):200. |
|
[13]
|
Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity[J]. Clin Cancer Res, 2006, 12(13):4090. |
|
[14]
|
Rice L, Pampo C, Lepler S, et al. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503[J]. Microvasc Res, 2011, 81(1):44. |
|
[15]
|
Folkes LK, Christlieb M, Madej E, et al. Oxidative metabolism of combretastatin A-1 producesquinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals[J]. Chem Res Toxicol, 2007, 20(12):1885. |
|
[16]
|
Sheng Y, Hua J, Pinney KG, et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis[J]. Int J Cancer, 2004, 111(4):604. |
|
[17]
|
Cummings J, Zweifel M, Smith N, et al. Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial[J]. Br J Cancer, 2012, 106(11):1766. |
|
[18]
|
Wankhede M, Dedeugd C, Siemann DW, et al. In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503[J]. Oncol Rep, 2010, 23(3):685. |
|
[19]
|
Mckeage MJ, Baguley BC. Disrupting established tumor blood vessels:an emerging therapeutic strategy for cancer[J]. Cancer, 2010, 116(8):1859. |
|
[20]
|
Patterson DM, Zweifel M, Middleton MR, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors[J]. Clin Cancer Res, 2012, 18(5):1415. |
|
[21]
|
Madlambayan GJ, Meacham AM, Hosaka K, et al. Leukemia regression by vascular disruption and antiangiogenic therapy[J]. Blood, 2010, 116(9):1539. |
|
[22]
|
Flynn BL, Gill GS, Grobelny DW, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties[J]. J Med Chem, 2011, 54(17):6014. |
|
[23]
|
Kremmidiotis G, Leske AF, Lavranos TC, et al. BNC105:a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy[J]. Mol Cancer Ther, 2010, 9(6):1562. |
|
[24]
|
Rischin D, Bibby DC, Chong G, et al. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P:a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation[J]. Clin Cancer Res, 2011, 17(15):5152. |
|
[25]
|
Sirisoma N, Kasibhatla S, Pervin A, et al. Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity[J]. J Med Chem, 2008, 51(15):4771. |
|
[26]
|
Sirisoma N, Pervin A, Zhang H, et al. Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration[J]. J Med Chem, 2009, 52(8):2341. |
|
[27]
|
Kasibhatla S, Baichwal V, Cai SX, et al. MPC-6827:a small-molecule inhibitor of microtubuleformation that is not a substrate for multidrug resistance pumps[J]. Cancer Res, 2007, 67(12):5865. |
|
[28]
|
Tsimberidou AM, Akerley W, Schabel MC, et al. Phase I clinical trial of MPC-6827(Azixa), a microtubule destabilizing agent, in patients with advanced cancer[J]. Mol Cancer Ther, 2010, 9(12):3410. |
|
[29]
|
Kemnitzer W, Drewe J, Jiang S, et al. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group[J]. J Med Chem, 2004, 47(25):6299. |
|
[30]
|
Kemnitzer W, Kasibhatla S, Jiang S, et al. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7-and 5-, 6-, 8-positions[J]. Bioorg Med Chem Lett, 2005, 15(21):4745. |
|
[31]
|
Read WL, Rosen P, Lee P, et al. Pharmacokinetic and pharmacodynamic results of a 4-hr iv administration phase I study with EPC2407, a novel vascular disrupting agent[J]. J Clin Oncol,2009, 27(15Suppl):3569. |
|
[32]
|
Fox E, Maris JM, Widemann BC, et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors[J]. Clin Cancer Res, 2008, 14(4):1111. |
|
[33]
|
Burns CJ, Fantino E, Phillips ID, et al. CYT997:a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo[J]. Mol Cancer Ther, 2009, 8(11):3036. |
|
[34]
|
Burge M, Francesconi A, Kotasek D, et al. Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent[J]. Invest New Drugs, 2012, 31(1):126. |
点击查看大图
下载:
